Kidney Cancer

Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

An expert explains the different types of kidney cancer surgeries, and what patients can expect to experience after the procedure.

Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study’s main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer.

A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors.

From “General Hospital” star Cameron Mathison discussing his cancer experience to Dame Deborah James and Hells Angels founder Sonny Barger dying of the disease, here’s what happened in the cancer space this week.

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

The aim of the early-stage trial is to identify the safety of the experimental drug as either a single-agent therapy as well as in combination with Keytruda in adults with multiple solid tumors.

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Laura Wood, M.S.N., RN, OCN, has "skill, dedication, boundless compassion and drive to improve the lives of those affected by kidney cancer."

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

Christine Amoroso, B.S.N., RN, OCN, figured out the best way to deliver direct-to-kidney treatment for her patients.

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.